Quantitative Imaging Workshop XIII:
Lung Cancer, COPD and Cardiovascular Disease
Exploring the Intersections
|DATES:||Monday, June 13, 2016||8:00 AM to 5:30 PM|
|Tuesday, June 14, 2016||8:00 AM to 1:00 PM|
WORKSHOP INFORMATION – WHAT YOU SHOULD KNOW
Since 2003, the Prevent Cancer Foundation has hosted a series of annual Workshops focused on the application of high resolution CT imaging data to lung cancer, COPD, and cardiovascular disease. Future workshops will continue to provide a forum for an exchange of ideas on the application of quantitative CT imaging to early disease management as well as for discussing policy and advocacy for lung cancer, COPD, and cardiovascular screening done responsibly.
The global roll-out of lung cancer screening services is increasing the need to establish quality standards for the low dose CT scans to ensure the reliability of accurately measuring lung nodules. While numerous CT scanners and protocols are more than capable of delivering a high quality CT scan with a low radiation dose, there remain CT instruments in routine use that may not be suitable for small nodule management. Adding to the challenge is that CT scanners are constantly evolving and changing. Achieving compliance with a standard is difficult, as there are multiple scanner settings, such as the type of reconstruction kernel or iterative reconstruction settings that are used. Therefore, in providing optimal clinical care, it is critical to establish how minimum quality specifications can be defined for lung cancer screening. Moving forward it is also important to understand how such specifications may affect imaging quality for co-occurring diseases and conditions such as COPD and coronary artery disease.
Quantitative Imaging Workshop XIII will be focused on two critical areas for progress with the application of quantitative CT imaging for lung cancer. The first issue involves an opportunity arising out of the national implementation of CT screening for lung cancer. Provisions are just being developed now as to how best to ensure the delivery of high quality screening services which will involve the development of data registries to track screening outcomes. It is becoming more evident that it is critical to store the full imaging data along with the clinical information to enable continuous quality control, additional research and sustain innovation for this critical new service. The second focus of the Workshop follows up on a theme that we have discussed at previous Workshops, as the use of quantitative imaging tools has the potential to cross fertilize and accelerate image processing research across lung cancer to other tobacco-induced diseases, including coronary artery disease and chronic obstructive pulmonary disease (COPD). The use of high resolution CT imaging is providing a window to obtain coronary calcium assessment, as we have considered previously. However, new CT scanners can be used to obtain higher quality and more quantitative coronary calcium assessment.
Beyond quality control, this clinical follow up/ CT image data base could be a profoundly important resource for enabling rapid research progress in looking at COPD and coronary artery disease in this tobacco-exposed high risk cohort engaged in screening. We will review the imaging factors, the care delivery factors and the public health policy dimension of this vibrant area. Many of the participants in this Workshop are experts on aspects of these issues so this is a great opportunity to share strategic perspectives and how we can determine approaches that will allow us to make the most rapid progress in this area.
This unique forum brings together key leaders in lung cancer, COPD, and cardiovascular disease early detection and development of new therapies for management of early-stage disease:
- Academic and community-based oncologists
- Pulmonologists and radiologists
- Experts in photonics and software development
- Federal policymakers and regulators
- Patient advocates
- Pharmaceutical and medical imaging industries
Workshop XIII will continue to build on the considerable progress achieved in earlier Workshops and address the recent cost/benefit analysis of lung cancer, COPD, and cardiovascular screening as well as explore the health policy implications of moving quantitative imaging to more precise early detection of lung cancer, COPD, and cardiovascular disease in high risk populations.